Sanofi S.A., FR0000120578

Sanofi posts duvakitug data as Sanofi stock sits 17.52 percent below its high

Published on 10/26/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Week 44 data covered 130 patients and two inflammatory bowel diseases. Sanofi stock costs EUR 74.88 on October 26, 2026, 0.79 percent above the Xetra close.

Clinical data and reporting dates

Sanofi reported Week 44 duvakitug results from 130 patients on October 20, 2026.
The Frankfurt insulin facility covers 36,000 square meters and targets full production in 2032.
Sanofi stock trades at EUR 74.88 at 10:48 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.79 percent above the Xetra close of October 23, 2026.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) was trading at EUR 74.88 at Lang & Schwarz on October 26, 2026 at 10:48 a.m. CEST, 0.79 percent above the Xetra close of October 23, 2026 at EUR 74.29. The price is 17.52 percent below its 52-week high of EUR 90.79. On October 20, 2026, Sanofi reported Week 44 data for duvakitug in ulcerative colitis and Crohn's disease.

Three events shape the pipeline

On October 6, 2026, Sanofi announced that its third-quarter 2026 results would be published on October 30, 2026. On October 19, 2026, the company broke ground on a EUR 2.0 billion insulin facility in Frankfurt with a 36,000-square-meter footprint, according to Sanofi. On October 20, 2026, the duvakitug update became the latest of the three developments, with 130 patients evaluated in the long-term extension study.

What does Week 44 show?

The clinical update gives investors a measurable view of durability rather than an approval decision. In ulcerative colitis, clinical remission reached 47 percent at the 450-milligram dose and 58 percent at 900 milligrams after 44 weeks. Clinical response was 82 percent and 87 percent, respectively. In Crohn's disease, endoscopic response was 41 percent at 450 milligrams and 55 percent at 900 milligrams. The company states that duvakitug remains under investigation and has not been evaluated by a regulatory authority.

Upcoming dates matter

Sanofi's next reporting date is October 30, 2026, when management will review third-quarter results in a webcast. The investor calendar also lists the Jefferies Global Healthcare Conference in London for November 17, 2026. Those dates give the market two near-term checkpoints for clinical progress, operating performance and the company's broader growth plans.

Stock remains below the yearly high

Sanofi's market capitalization was EUR 89.7 billion as of October 26, 2026, while its 52-week range stood at EUR 69.75 to EUR 90.79. The current quote is therefore above the year's low but still materially below the high, leaving the clinical data and the upcoming results as separate information points for investors.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.